Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025PharmaciaOpen Access

In situ development of an artificial intelligence (AI) model for early detection of adverse drug reactions (ADRs) to ensure drug safety

View Full Paper
Ask AI
Bookmark
Share

Authors

VRVeselina RusevaSDStanimir DobrevVGVioleta Getova-Kolarova

Discussion

Loading...

Member takes

Overview

Observational analysis developed an AI model for predicting adverse drug reactions, suggesting better drug safety monitoring.

Key Points

  • The AI model predicts adverse drug reactions based on molecular structure and criteria, enhancing patient safety.
  • Using various databases, the model integrates data to provide timely risk identification of drug safety issues.
  • A neural network was implemented to improve and support safety assessments in the pharmacovigilance process.
  • AI-assisted modeling may strengthen drug monitoring strategies, though limitations in data accuracy remain.

Cite This Study

Ruseva et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d6478fef6https://doi.org/10.3897/pharmacia.72.e160997
View Full Paper
Ask AI
Bookmark
Share